biovail corp. and sec Resources | BNET
On CBS.com: A woman murders her boyfriend

BNET Industries

Biovail Corp. is in the Pharma Industry

Latest News and Analysis

  • Biovail Updates Status of SEC Inquiry

    TORONTO -- Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that the U.S. Securities and Exchange Commission SEC has issued a formal order of investigation related to the previously disclosed informal inquiry initiated in November 2003 which sought historical financial and related information, including, but not limited to the Company's accounting and financial...

    Research articles 2005-03-04

    Tags: Biovail Corp., SEC

  • Biovail Updates Status of SEC Inquiry.

    TORONTO, Mar 4, 2005 CCNMatthews via COMTEX TORONTO, Mar 4, 2005 CCNMatthews via COMTEX

    Research articles 2005-03-04

    Tags: Biovail Corp., SEC

  • Biovail Confirms Informal Inquiry by SEC.

    TORONTO, ONTARIO, Nov 20, 2003 CCNMatthews via COMTEX TORONTO, ONTARIO, Nov 20, 2003 CCNMatthews via COMTEX

    Research articles 2003-11-21

    Tags: Biovail Corp., SEC

Additional Resources

  • Biovail Announces U.S. Availability of Xenazine® Tablets

    TORONTO -- Biovail Corporation today announced that Xenazine[R] tablets, an orphan drug recently approved by the U.S. Food and Drug Administration FDA for the treatment of chorea associated with Huntington's disease HD, is now available throughout the United States. Xenazine[R] is the first and only FDA-approved treatment for any HD-related...

    Articles 2008-11-24

  • Biovail to Participate at Upcoming Conferences

    TORONTO -- Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that the Company will participate at the 2008 Annual Credit Suisse Health Care Conference at the Arizona Biltmore Resort in Phoenix, Arizona and at the Lazard Capital Markets 5th Annual Healthcare Conference at the St. Regis Hotel in New York City. ...

    Articles 2008-11-11

  • Biovail Reports Third-Quarter 2008 Financial Results

    Third-Quarter 2008 Revenues of $181.1 Million; Third-Quarter 2008 Net Income of $48.4 Million; U.S. GAAP EPS of $0.31; Acquires First Specialty Central Nervous System Product for Launch in 2008; Files ANDA for Fenofibrate Tablets; Strengthened Management Team with Chief Scientific Officer ...

    Articles 2008-11-06

  • Biovail Declares Quarterly Dividend

    Total Dividends Declared Since December 2005 of $4.50 per share TORONTO -- Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that the Company's Board of Directors has declared a quarterly cash dividend of US$0.375 per share payable on January 5, 2009, to shareholders of record at the close of business December...

    Articles 2008-11-06

  • Biovail Appoints Dr. H. Christian Fibiger Senior Vice-President, Chief Scientific Officer

    TORONTO -- Biovail Corporation (NYSE, TSX: BVF) today announced the appointment of Dr. H. Christian Fibiger as Senior Vice-President, Chief Scientific Officer of Biovail Laboratories International SRL BLS, the Company's principal operating subsidiary. The appointment is effective November 24, 2008. Dr. Fibiger brings a wealth of academic and...

    Articles 2008-11-06

  • Biovail Announces Third-Quarter 2008 Earnings Release, Conference-Call Details

    TORONTO -- Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that it will host a conference call and Webcast on Thursday, November 6, 2008, at 8:30 a.m. EST, for Company executives to discuss third-quarter 2008 financial and operational results. Following the discussion, Biovail executives will address inquiries from investment analysts....

    Articles 2008-10-28

  • Generic Wellbutrin to get review

    The Food and Drug Administration says it is ready to conduct a human trial to resolve complaints concerning genetic Wellbutrin XL just months after declaring the Impax Laboratories Inc.-made generic drug to be safe. The brand version is made by Biovail Corp. and sold by GlaxoSmithKline PLC. Over 100 complaints...

    Articles 2008-10-27

  • Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Biovail Corporation to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the December 8, 2008 Lead Plaintiff Deadline

    Brower Piven, A Professional Corporationannounces that a class action lawsuit has been commenced in the UnitedStates District Court for the Southern District of New York on behalf ofpurchasers of the securities of Biovail Corporation ("Biovail" or the"Company") (NYSE: BVF) during the period between December 14, 2006 and July19, 2007, inclusive...

    Articles 2008-10-15

  • Wall Street Media Presents an Exclusive Video from Natixis Bleichroeder 2nd Annual Hidden Gems Conference

    NEW YORK -- Wall Street Media presents an exclusive video of Mr. Joseph J. Corasanti, CEO of CONMED Corporation, (NASDAQ: CNMD) discussing their electro surgery products, and branching out into orthopedics. Please visit the following link to view the video: http://www.wsmco.com/show.aspx?1130_Up_and_Coming_Stocks Wall Street Media...

    Articles 2008-10-13

  • INVESTOR ALERT: KGS Notifies Biovail Corporation Purchasers With Losses Greater Than $300,000, of Lead Plaintiff Application Deadline in Securities Class Action Lawsuit -- BVF

    Kahn Gauthier Swick, LLC ("KGS") announcesthat a securities class action lawsuit was filed in the United StatesDistrict Court for the Southern District of New York, on behalf ofpurchasers of the securities and common stock of Biovail Corporation("Biovail") (NYSE: BVF) during the period between December 14, 2006 andJuly 19, 2007, inclusive...

    Articles 2008-10-11

  • Biovail Comments on Filing of Lawsuit

    TORONTO -- Biovail Corporation (NYSE, TSX: BVF) today announced that it has been notified that a proposed securities class action lawsuit has been filed in the U.S. District Court Southern District of New York against the Company, its Chairman and two former officers. The complaint has been filed on behalf...

    Articles 2008-10-09

  • Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit against Biovail Corporation

    SAN DIEGO -- Coughlin Stoia Geller Rudman & Robbins LLP ("Coughlin Stoia") (http://www.csgrr.com/cases/biovailcorp/) today announced that a class action has been commenced on behalf of an institutional investor in the United States District Court for the Southern District of New York on behalf of purchasers of Biovail Corporation ("Biovail") (NYSE:BVF)...

    Articles 2008-10-09

  • page 1 of 1

Sort byClose

advertisement
Industry Transcripts by Seeking Alpha
Biovail Corp. Company Info

NAICS Code

Pharmaceutical Preparation Manufacturing: 325412
advertisement